Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 17   

Articles published

KYTH 34.27 -0.35 (-1.01%)
price chart
KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New ...
CALABASAS, Calif., July 10, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid), has been accepted for filing by the U.S.
Related articles »  
Insider Selling: Nathaniel E. David Sells 1778 Shares of KYTHERA ...
Analysts expect that KYTHERA Biopharmaceuticals will post $-3.33 EPS for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
KYTHERA Biopharmaceuticals CEO Keith R. Leonard Unloads 8925 Shares ...
Analysts expect that KYTHERA Biopharmaceuticals will post $-3.33 EPS for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Related articles »  
Insider Selling: John W. Smither Unloads 2250 Shares of KYTHERA ...
On average, analysts predict that KYTHERA Biopharmaceuticals will post $-3.33 earnings per share for the current fiscal year. KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and ...
Trader's Watch List � American Airlines (NASDAQ:AAL), Bed Bath & Beyond ...
KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) on 10 July announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid), has been accepted for filing by the U.S.
Drug Most Volatile Stocks: Heron Therapeutics (NASDAQ:HRTX), Tetraphase ...
On July 10, 2014, KYTHERA Biopharmaceuticals, Inc. issued a press release announcing that its New Drug Application for ATX-101 (deoxycholic acid) has been accepted for filing by the U.S.
FDA Accepts Kythera Drug for Review
Kythera Biopharmaceuticals Inc. announced that the Food and Drug Administration has accepted its application for ATX-101, an experimental drug that dissolves chin fat.
Interesting Analysis: MannKind Corporation (NASDAQ:MNKD), Intercept ...
Stocks that have Phase III data that could lead to an approval include Acadia Pharmaceuticals (ACAD), Alexion Pharmaceuticals (ALXN), Intercept, InterMune (ITMN), Kythera Biopharmaceuticals (KYTH), Merrimack Pharmaceuticals (MACK), and Relypsa ...
Related articles »